BioCryst Pharmaceuticals (BCRX) Upgraded by Zacks Investment Research to Hold

BioCryst Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  BioCryst Pharmaceuticals Upgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

Shares of BioCryst Pharmaceuticals traded up $0.28 on Wednesday, reaching $14.99. 2521433 shares of the stock traded hands, compared to its average volume of 2344026. Shares of BioCryst Pharmaceuticals were trading at $14.99 on Wednesday. The firm’s 50 day moving average is $15.22 and its 200 day moving average is $13.22.BioCryst Pharmaceuticals has a 12 month low of $14.59 and a 12 month high of $18.48. While on yearly highs and lows, BioCryst Pharmaceuticals’s today has traded high as $15.01 and has touched $14.59 on the downward trend. See More Analyst Rating at: RATING

BioCryst Pharmaceuticals Earnings and What to expect: 

BioCryst Pharmaceuticals last announced its earnings results on August 5th, 2021. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.02. The business earned $49.96 million during the quarter, compared to analysts’ expectations of $31.37 million. BioCryst Pharmaceuticals has generated ($1.09) earnings per share over the last year (($1.20) diluted earnings per share). Earnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($1.22) to ($0.82) per share. BioCryst Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($1.22) to ($0.82) per share. The P/E ratio of BioCryst Pharmaceuticals is -12.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of BioCryst Pharmaceuticals is -12.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

BioCryst Pharmaceuticals (BCRX) Moving Average Technical Analysis

5 day Moving Average is $14.51 And 5 day price change is $1.46 (10.79%)  with average volume for 5 day average is 2,145,620. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $14.63 and 20 day price change is -$0.08 (-0.53%) and average 20 day moving volume is 2,456,970. 50 day moving average is $15.22  and 50 day price change is -$1.77 ( -10.56%)  and with average volume for 50 days is : 2,785,288. 200 day moving average is $13.22  and 200 day price change is $7.81 (108.77%)  and with average volume for 200 days is : 4,461,505.

Other owners latest trading in BioCryst Pharmaceuticals :

  • On 10/13/2021 shares held by Edge Wealth Management LLC were 25,000 which equates to market value of $0.36M and appx 0.10% owners of BioCryst Pharmaceuticals
  • On 10/12/2021 shares held by First Hawaiian Bank were 30,765 which equates to market value of $0.44M and appx 0.00% owners of BioCryst Pharmaceuticals
  • On 9/24/2021 shares held by Thrivent Financial for Lutherans were 115,470 which equates to market value of $1.83M and appx 0.00% owners of BioCryst Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 58.33% for BioCryst Pharmaceuticals

See More Analyst Rating at: RATING